Esomeprazole

Synonimy: Nexium, Esomeprazole magnesium, (S)-Omeprazole, 5-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole

Esomeprazole is the S-enantiomer of omeprazole, a proton pump inhibitor (PPI) that selectively inhibits the gastric H+/K+-ATPase enzyme system. Its structure features a benzimidazole core linked via a sulfinyl group to a pyridine ring, with the S-configuration at the sulfoxide center conferring improved pharmacokinetic properties compared to the racemic mixture.

As a chiral switch of omeprazole, esomeprazole offers higher and more consistent bioavailability due to reduced first-pass metabolism by CYP2C19. It is primarily used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. For pharmaceutical manufacturers, esomeprazole is a key API for generic formulations, including delayed-release capsules and injectable forms.

With the expiration of key patents, demand for high-purity esomeprazole from generic drug producers has surged. LyvBio supplies esomeprazole with reliable quality and full regulatory support, ensuring seamless integration into your production lines.

Struktura chemiczna i właściwości

Esomeprazole is a substituted benzimidazole derivative. The molecule contains a sulfinyl group that is chiral, and the S-enantiomer is the active pharmaceutical ingredient. It is a weak base, with pKa values of 4.0 and 9.0, and is practically insoluble in water at neutral pH but becomes soluble under acidic conditions. The compound is sensitive to light and moisture, and should be stored in tightly sealed containers away from direct sunlight.

Mechanizm działania

• Irreversible proton pump inhibition: Esomeprazole accumulates in the acidic environment of gastric parietal cells, where it is converted to the active sulfenamide form, which binds covalently to cysteine residues on the H+/K+-ATPase, blocking acid secretion.
• Enantioselective metabolism: The S-enantiomer is less dependent on CYP2C19 for metabolism, leading to higher plasma concentrations and more predictable efficacy.
• Rapid onset: Peak plasma levels are reached within 1-2 hours after oral administration, providing fast symptom relief.
• Long duration: The covalent binding results in prolonged inhibition of acid secretion, allowing once-daily dosing.

Quality Specifications (QC Tests)

Dostawa i dokumentacja

• Pojemność: 5 metric tons per month
• Czas realizacji: 3–5 dni roboczych (towary dostępne w magazynie)
• Dokumentacja: COA, MSDS, TDS, and regulatory support available upon request.
• Opakowanie: beczki na włókna o pojemności 25 kg z podwójnymi wkładami z polietylenu lub opakowania dostosowane do indywidualnych potrzeb w przypadku niewielkich ilości.

Najczęściej zadawane pytania

What is the minimum order quantity (MOQ)?

Our standard MOQ is 1 kg for stock items, but we can accommodate smaller quantities for research and development purposes. Please contact us for details.

What is the delivery time?

For stock items, delivery is typically 3-5 business days from order confirmation. We maintain sufficient inventory to ensure prompt shipment.

Can you provide a COA and samples?

Yes, we provide a COA for each batch. Samples are available upon request, usually shipped within 1-2 days.

What are the packaging options?

We offer 25 kg fiber drums as standard. For smaller orders, we can pack in 1 kg or 5 kg aluminum foil bags, or as per your requirements.

Contact & Ordering Information

• Company: LyvBio Co., Ltd.
• Address: Room 5-0203, Courtyard 205, Lianhu District, Xi’an, Shaanxi, China
• Email: info@lyvbio.com
• Phone: +86-29-65816888

send us your specification for a quotation.